Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy

Journal of Neurology

Volumn 264, Issue 5, 2017, Pages 839-847

  Nakatsuji, Hideaki ^a   Araki, Amane ^a,b   Hashizume, Atsushi ^a   Hijikata, Yasuhiro ^a   Yamada, Shinichiro ^a   Inagaki, Tomonori ^a   Suzuki, Keisuke ^a,c   Banno, Haruhiko ^a   Suga, Noriaki ^a,d   Okada, Yohei ^e,f   Ohyama, Manabu ^f   Nakagawa, Tohru ^g   Kishida, Ken ^h,i   Funahashi, Tohru ^h   Shimomura, Iichiro ^h   Okano, Hideyuki ^f   Katsuno, Masahisa ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kasugai Municipal Hospital   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^d Sarashina Rehabilitation Clinic   (Japan)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HITACHI LTD   (Japan)

^h OSAKA UNIVERSITY   (Japan)

ⁱ Kishida Clinic   (Japan)

Author keywords

Insulin receptor; Insulin resistance; SBMA; Spinal and bulbar muscular atrophy

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR BETA; INSULIN RECEPTOR SUBSTRATE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ARTICLE; ASSESSMENT OF HUMANS; BLOOD PRESSURE; BODY MASS; BULBAR PARALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FIBROBLAST; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INTRAPERITONEAL FAT; KENNEDY DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; MOLECULAR PATHOLOGY; MOTOR PERFORMANCE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; CASE CONTROL STUDY; COMPLICATION; GENETICS; METABOLIC DISORDER; METABOLISM; MOTOR ACTIVITY; MOTOR DYSFUNCTION; PATHOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SKELETAL MUSCLE; STATISTICS;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; MALE; METABOLIC DISEASES; MIDDLE AGED; MOTOR ACTIVITY; MOVEMENT DISORDERS; MUSCLE, SKELETAL; MUSCULAR DISORDERS, ATROPHIC; RECEPTOR, INSULIN; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TRIGLYCERIDES;

EID: 85013408571     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-017-8405-3     Document Type: Article

References (41)

1. Katsuno M, Tanaka F, Adachi H et al (2012) Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 99:246–256
2. Giorgetti E, Lieberman AP (2016) Polyglutamine androgen receptor-mediated neuromuscular disease. Cell Mol Life Sci 73(21):3991–3999
3. La Spada AR, Wilson EM, Lubahn DB et al (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77–79
4. Katsuno M, Adachi H, Kume A et al (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843–854
5. Adachi H, Katsuno M, Minamiyama M et al (2005) Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 128:659–670
6. Sorarù G, D’Ascenzo C, Polo A et al (2008) Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci 264:100–105
7. Dejager S, Bry-Gauillard H, Bruckert E et al (2002) A comprehensive endocrine description of Kennedy’s disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 87:3893–3901
8. Rhodes LE, Freeman BK, Auh S et al (2009) Clinical features of spinal and bulbar muscular atrophy. Brain 132:3242–3251
9. Hashizume A, Katsuno M, Banno H et al (2012) Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 135:2838–2848
10. Vagelatos NT, Eslick GD (2013) Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 35:152–160
11. Xu Q, Park Y, Huang X et al (2011) Diabetes and risk of Parkinson’s disease. Diabetes Care 34:910–915
12. Dupuis L, Corcia P, Fergani A et al (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70:1004–1009
13. Kioumourtzoglou MA, Rotem RS, Seals RM et al (2015) Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol 72:905–911
14. Shimojo D, Onodera K, Doi-Torii Y et al (2015) Rapid, efficient, and simple motor neuron differentiation from human pluripotent stem cells. Mol Brain 8:79
15. Hijikata H, Katsuno M, Suzuki K et al (2016) Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol 3:537–546
16. Nakatsuji H, Kishida K, Kitamura T et al (2010) Dysregulation of glucose, insulin, triglyceride, blood pressure, and oxidative stress after an oral glucose tolerance test in men with abdominal obesity. Metabolism 59:520–526
17. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
18. Querin G, Bertolin C, Da Re E et al (2016) Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J Neurol Neurosurg Psychiatry 87:810–816
19. Iida M, Katsuno M, Nakatsuji H et al (2015) Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors. Hum Mol Genet 24:314–329
20. Yu IC, Lin HY, Sparks JD et al (2014) Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes 63:3180–3188
21. Maeda N, Shimomura I, Kishida K et al (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731–737
22. Cortes CJ, Ling SC, Guo LT et al (2014) Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 82:295–307
23. Palazzolo I, Stack C, Kong L et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63:316–328
24. Srikanthan P, Hevener AL, Karlamangla AS (2010) Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS One 5:e10805
25. Wijngaarden MA, van der Zon GC, van Dijk KW et al (2013) Effects of prolonged fasting on AMPK signaling, gene expression, and mitochondrial respiratory chain content in skeletal muscle from lean and obese individuals. Am J Physiol Endocrinol Metab 304:E1012–E1021
26. Swan JW, Anker SD, Walton C et al (1997) Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30:527–532
27. Ouchi N, Parker JL, Lugus JJ et al (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85–97
28. Nishizawa H, Shimomura I, Kishida K et al (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741
29. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3:169–178
30. Santiago JA, Potashkin JA (2013) Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol Med 19:176–186
31. Lalić NM, Marić J, Svetel M et al (2008) Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65:476–480
32. Lalić NM, Dragasević N, Stefanova E et al (2010) Impaired insulin sensitivity and secretion in normoglycemic patients with spinocerebellar ataxia type 1. Mov Disord 25:1976–1980
33. Yu Z, Wang AM, Adachi H et al (2011) Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice. PLoS Genet 7:e1002321
34. Navarro G, Allard C, Xu W et al (2015) The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring) 23:713–719
35. Chang PY, Benecke H, Le Marchand-Brustel Y et al (1994) Expression of a dominant-negative mutant human insulin receptor in the muscle of transgenic mice. J Biol Chem 269:16034–16040
36. Hilder TL, Tou JC, Grindeland RE et al (2003) Phosphorylation of insulin receptor substrate-1 serine 307 correlates with JNK activity in atrophic skeletal muscle. FEBS Lett 553:63–67
37. Minamiyama M, Katsuno M, Adachi H et al (2012) Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nat Med 18:1531–1538
38. Lee CG, Boyko EJ, Strotmeyer ES et al (2011) Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. J Am Geriatr Soc 59:1217–1224
39. Kalonia H, Kumar P, Kumar A (2010) Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington’s disease. Pharmacol Biochem Behav 96:115–124
40. Dehmer T, Heneka MT, Sastre M et al (2004) Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88:494–501
41. Kiaei M, Kipiani K, Chen J et al (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191:331–336